Alluvi, known as BI 4744, offers a significant development in weight control therapy. This dual activator targeting both glucagon-like peptide-1 and GIP receptors demonstrates remarkable efficacy in clinical trials, https://alluvi143523.jiliblog.com/99733133/alluvi-a-in-depth-dive-into-the-drug-s-prospects